Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
foritinib
- Development stage
- Phase 2
- Lead developer
- Fosun Pharma
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Foritinib is a highly potent, orally active small molecule inhibitor targeting anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1). It is designed to treat non-small cell lung cancer (NSCLC), particularly in patients with ALK-positive or ROS1-positive locally advanced or metastatic disease. Foritinib demonstrates strong central nervous system (CNS) penetration and has shown robust efficacy in controlling CNS metastases. Clinical trials have reported high objective response rates and improved progression-free survival compared to crizotinib, with a favorable safety profile. The drug was developed by Shanghai Fosun Pharmaceutical and Chongqing Fochon Pharmaceutical/Shanghai Institute of Materia Medica[1][5][6][8].
- Brand names
- Foritinib
- Other names
- foritinib succinateFuruitini succinate
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on foritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on foritinib.